{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:42:28Z","timestamp":1789846948291,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI22931"],"award-info":[{"award-number":["RO1 AI22931"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Invasive candidiasis is an increasingly frequent cause of serious and often fatal infections in hospitalized and immunosuppressed patients. Mortality rates associated with these infections have risen sharply due to the emergence of multidrug resistant (MDR) strains of <jats:italic>C<\/jats:italic>. <jats:italic>albicans<\/jats:italic> and other <jats:italic>Candida<\/jats:italic> spp., highlighting the urgent need of new antifungal therapies. Rhesus theta (\u03b8) defensin-1 (RTD-1), a natural macrocyclic antimicrobial peptide, was recently shown to be rapidly fungicidal against clinical isolates of MDR <jats:italic>C<\/jats:italic>. <jats:italic>albicans in vitro<\/jats:italic>. Here we found that RTD-1 was rapidly fungicidal against blastospores of fluconazole\/caspofungin resistant <jats:italic>C<\/jats:italic>. <jats:italic>albicans<\/jats:italic> strains, and was active against established <jats:italic>C<\/jats:italic>. <jats:italic>albicans<\/jats:italic> biofilms <jats:italic>in vitro<\/jats:italic>. <jats:italic>In vivo<\/jats:italic>, systemic administration of RTD-1, initiated at the time of infection or 24\u2009h post-infection, promoted long term survival in candidemic mice whether infected with drug-sensitive or MDR strains of <jats:italic>C<\/jats:italic>. <jats:italic>albicans<\/jats:italic>. RTD-1 induced an early (4\u2009h post treatment) increase in neutrophils in naive and infected mice. <jats:italic>In vivo<\/jats:italic> efficacy was associated with fungal clearance, restoration of dysregulated inflammatory cytokines including TNF-\u03b1, IL-1\u03b2, IL-6, IL-10, and IL-17, and homeostatic reduction in numbers of circulating neutrophils and monocytes. Because these effects occurred using peptide doses that produced maximal plasma concentrations (Cmax) of less than 1% of RTD-1 levels required for <jats:italic>in vitro<\/jats:italic> antifungal activity in 50% mouse serum, while inducing a transient neutrophilia, we suggest that RTD-1 mediates its antifungal effects <jats:italic>in vivo<\/jats:italic> by host directed mechanisms rather than direct fungicidal activity. Results of this study suggest that \u03b8-defensins represent a new class of host-directed compounds for treatment of disseminated candidiasis.<\/jats:p>","DOI":"10.1038\/s41598-019-53402-z","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T11:03:48Z","timestamp":1573815828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-3439","authenticated-orcid":false,"given":"Virginia","family":"Basso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dat Q.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin B.","family":"Schaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-230X","authenticated-orcid":false,"given":"Yoshihiro","family":"Eriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-8407","authenticated-orcid":false,"given":"Diana","family":"Ngole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Cabebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Beringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 J.","family":"Ouellette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Selsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"53402_CR1","doi-asserted-by":"publisher","first-page":"165rv113","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"GD Brown","year":"2012","unstructured":"Brown, G. D. et al. Hidden killers: human fungal infections. Sci Transl Med 4, 165rv113, https:\/\/doi.org\/10.1126\/scitranslmed.3004404 (2012).","journal-title":"Sci Transl Med"},{"key":"53402_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","volume":"23","author":"DW Denning","year":"1996","unstructured":"Denning, D. W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23, 608\u2013615, https:\/\/doi.org\/10.1093\/clinids\/23.3.608 (1996).","journal-title":"Clin Infect Dis"},{"issue":"490","key":"53402_CR3","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1016\/j.cmi.2014.12.021","volume":"21","author":"M Slavin","year":"2015","unstructured":"Slavin, M. et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin Microbiol Infect 21(490), e491\u2013410, https:\/\/doi.org\/10.1016\/j.cmi.2014.12.021 (2015).","journal-title":"Clin Microbiol Infect"},{"key":"53402_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"MA Pfaller","year":"2007","unstructured":"Pfaller, M. A. & Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133\u2013163, https:\/\/doi.org\/10.1128\/CMR.00029-06 (2007).","journal-title":"Clin Microbiol Rev"},{"key":"53402_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TCRM.S40160","volume":"10","author":"N Yapar","year":"2014","unstructured":"Yapar, N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 10, 95\u2013105, https:\/\/doi.org\/10.2147\/TCRM.S40160 (2014).","journal-title":"Ther Clin Risk Manag"},{"key":"53402_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ncprheum0336","volume":"2","author":"KL Winthrop","year":"2006","unstructured":"Winthrop, K. L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2, 602\u2013610, https:\/\/doi.org\/10.1038\/ncprheum0336 (2006).","journal-title":"Nat Clin Pract Rheumatol"},{"key":"53402_CR7","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.4049\/jimmunol.1202526","volume":"190","author":"LB Rosen","year":"2013","unstructured":"Rosen, L. B. et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 190, 3959\u20133966, https:\/\/doi.org\/10.4049\/jimmunol.1202526 (2013).","journal-title":"J Immunol"},{"key":"53402_CR8","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMra1315399","volume":"373","author":"BJ Kullberg","year":"2015","unstructured":"Kullberg, B. J. & Arendrup, M. C. Invasive Candidiasis. N Engl J Med 373, 1445\u20131456, https:\/\/doi.org\/10.1056\/NEJMra1315399 (2015).","journal-title":"N Engl J Med"},{"issue":"4","key":"53402_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jof2040026","volume":"2","author":"Kaila Pianalto","year":"2016","unstructured":"Pianalto, K. M. & Alspaugh, J. A. New Horizons in Antifungal Therapy. J Fungi (Basel) 2, https:\/\/doi.org\/10.3390\/jof2040026 (2016).","journal-title":"Journal of Fungi"},{"key":"53402_CR10","first-page":"548","volume":"101","author":"A Duerr","year":"2003","unstructured":"Duerr, A. et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 101, 548\u2013556 (2003).","journal-title":"Obstet Gynecol"},{"key":"53402_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/jhin.2001.1131","volume":"50","author":"W Hope","year":"2002","unstructured":"Hope, W., Morton, A. & Eisen, D. P. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 50, 56\u201365, https:\/\/doi.org\/10.1053\/jhin.2001.1131 (2002).","journal-title":"J Hosp Infect"},{"key":"53402_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1590\/S0036-46651995000500004","volume":"37","author":"M Nucci","year":"1995","unstructured":"Nucci, M. et al. Fungal infections in neutropenic patients. A 8-year prospective study. Rev Inst Med Trop Sao Paulo 37, 397\u2013406 (1995).","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"53402_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tim.2014.01.001","volume":"22","author":"D Armstrong-James","year":"2014","unstructured":"Armstrong-James, D., Meintjes, G. & Brown, G. D. A neglected epidemic: fungal infections in HIV\/AIDS. Trends Microbiol 22, 120\u2013127, https:\/\/doi.org\/10.1016\/j.tim.2014.01.001 (2014).","journal-title":"Trends Microbiol"},{"key":"53402_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrd3074","volume":"9","author":"L Ostrosky-Zeichner","year":"2010","unstructured":"Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C. & Rex, J. H. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9, 719\u2013727, https:\/\/doi.org\/10.1038\/nrd3074 (2010).","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"53402_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijantimicag.2006.03.012","volume":"27","author":"TR Rogers","year":"2006","unstructured":"Rogers, T. R. Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 27(Suppl 1), 7\u201311, https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.03.012 (2006).","journal-title":"Int J Antimicrob Agents"},{"key":"53402_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-micro-091014-104330","volume":"69","author":"CJ Nobile","year":"2015","unstructured":"Nobile, C. J. & Johnson, A. D. Candida albicans Biofilms and Human Disease. Annu Rev Microbiol 69, 71\u201392, https:\/\/doi.org\/10.1146\/annurev-micro-091014-104330 (2015).","journal-title":"Annu Rev Microbiol"},{"key":"53402_CR17","doi-asserted-by":"publisher","first-page":"ftw018","DOI":"10.1093\/femspd\/ftw018","volume":"74","author":"C Tsui","year":"2016","unstructured":"Tsui, C., Kong, E. F. & Jabra-Rizk, M. A. Pathogenesis of Candida albicans biofilm. Pathog Dis 74, ftw018, https:\/\/doi.org\/10.1093\/femspd\/ftw018 (2016).","journal-title":"Pathog Dis"},{"key":"53402_CR18","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1128\/JB.183.18.5385-5394.2001","volume":"183","author":"J Chandra","year":"2001","unstructured":"Chandra, J. et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183, 5385\u20135394 (2001).","journal-title":"J Bacteriol"},{"key":"53402_CR19","first-page":"431","volume":"5","author":"RM Dominic","year":"2007","unstructured":"Dominic, R. M., Shenoy, S. & Baliga, S. Candida biofilms in medical devices: evolving trends. Kathmandu Univ Med J (KUMJ) 5, 431\u2013436 (2007).","journal-title":"Kathmandu Univ Med J (KUMJ)"},{"key":"53402_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bcp.2016.11.019","volume":"133","author":"S Campoy","year":"2017","unstructured":"Campoy, S. & Adrio, J. L. Antifungals. Biochem Pharmacol 133, 86\u201396, https:\/\/doi.org\/10.1016\/j.bcp.2016.11.019 (2017).","journal-title":"Biochem Pharmacol"},{"key":"53402_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1128\/CMR.12.4.501","volume":"12","author":"MA Ghannoum","year":"1999","unstructured":"Ghannoum, M. A. & Rice, L. B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12, 501\u2013517 (1999).","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"53402_CR22","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.3402\/jom.v3i0.5771","volume":"3","author":"David Williams","year":"2011","unstructured":"Williams, D. & Lewis, M. Pathogenesis and treatment of oral candidosis. J Oral Microbiol 3, https:\/\/doi.org\/10.3402\/jom.v3i0.5771 (2011).","journal-title":"Journal of Oral Microbiology"},{"key":"53402_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14787210.2016.1199272","volume":"14","author":"FP Tverdek","year":"2016","unstructured":"Tverdek, F. P., Kofteridis, D. & Kontoyiannis, D. P. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther 14, 765\u2013776, https:\/\/doi.org\/10.1080\/14787210.2016.1199272 (2016).","journal-title":"Expert Rev Anti Infect Ther"},{"key":"53402_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2217\/14622416.9.5.561","volume":"9","author":"J Meletiadis","year":"2008","unstructured":"Meletiadis, J., Chanock, S. & Walsh, T. J. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics 9, 561\u2013584, https:\/\/doi.org\/10.2217\/14622416.9.5.561 (2008).","journal-title":"Pharmacogenomics"},{"key":"53402_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0966-842X(02)00002-1","volume":"11","author":"LJ Douglas","year":"2003","unstructured":"Douglas, L. J. Candida biofilms and their role in infection. Trends Microbiol 11, 30\u201336 (2003).","journal-title":"Trends Microbiol"},{"key":"53402_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1128\/CMR.17.2.255-267.2004","volume":"17","author":"EM Kojic","year":"2004","unstructured":"Kojic, E. M. & Darouiche, R. O. Candida infections of medical devices. Clin Microbiol Rev 17, 255\u2013267 (2004).","journal-title":"Clin Microbiol Rev"},{"key":"53402_CR27","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1126\/science.aaa6097","volume":"347","author":"DW Denning","year":"2015","unstructured":"Denning, D. W. & Bromley, M. J. Infectious Disease. How to bolster the antifungal pipeline. Science 347, 1414\u20131416, https:\/\/doi.org\/10.1126\/science.aaa6097 (2015).","journal-title":"Science"},{"key":"53402_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1517\/14728214.2016.1155554","volume":"21","author":"JR Perfect","year":"2016","unstructured":"Perfect, J. R. \u201cIs there an emerging need for new antifungals?\u201d. Expert Opin Emerg Drugs 21, 129\u2013131, https:\/\/doi.org\/10.1517\/14728214.2016.1155554 (2016).","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"53402_CR29","doi-asserted-by":"publisher","first-page":"a019703","DOI":"10.1101\/cshperspect.a019703","volume":"4","author":"T. Roemer","year":"2014","unstructured":"Roemer, T. & Krysan, D. J. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 4, https:\/\/doi.org\/10.1101\/cshperspect.a019703 (2014).","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"53402_CR30","doi-asserted-by":"publisher","first-page":"27014","DOI":"10.1074\/jbc.R112.346098","volume":"287","author":"RI Lehrer","year":"2012","unstructured":"Lehrer, R. I., Cole, A. M. & Selsted, M. E. theta-Defensins: cyclic peptides with endless potential. J Biol Chem 287, 27014\u201327019, https:\/\/doi.org\/10.1074\/jbc.R112.346098 (2012).","journal-title":"J Biol Chem"},{"key":"53402_CR31","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1128\/IAI.01100-08","volume":"76","author":"AE Garcia","year":"2008","unstructured":"Garcia, A. E., Osapay, G., Tran, P. A., Yuan, J. & Selsted, M. E. Isolation, synthesis, and antimicrobial activities of naturally occurring theta-defensin isoforms from baboon leukocytes. Infect Immun 76, 5883\u20135891, https:\/\/doi.org\/10.1128\/IAI.01100-08 (2008).","journal-title":"Infect Immun"},{"key":"53402_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1126\/science.286.5439.498","volume":"286","author":"YQ Tang","year":"1999","unstructured":"Tang, Y. Q. et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 286, 498\u2013502 (1999).","journal-title":"Science"},{"key":"53402_CR33","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1074\/jbc.M109117200","volume":"277","author":"D Tran","year":"2002","unstructured":"Tran, D. et al. Homodimeric theta-defensins from rhesus macaque leukocytes: isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides. J Biol Chem 277, 3079\u20133084, https:\/\/doi.org\/10.1074\/jbc.M109117200 (2002).","journal-title":"J Biol Chem"},{"key":"53402_CR34","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.peptides.2003.07.023","volume":"24","author":"TX Nguyen","year":"2003","unstructured":"Nguyen, T. X., Cole, A. M. & Lehrer, R. I. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 24, 1647\u20131654, https:\/\/doi.org\/10.1016\/j.peptides.2003.07.023 (2003).","journal-title":"Peptides"},{"key":"53402_CR35","doi-asserted-by":"publisher","first-page":"e51337","DOI":"10.1371\/journal.pone.0051337","volume":"7","author":"JB Schaal","year":"2012","unstructured":"Schaal, J. B. et al. Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis. PLoS One 7, e51337, https:\/\/doi.org\/10.1371\/journal.pone.0051337 (2012).","journal-title":"PLoS One"},{"key":"53402_CR36","doi-asserted-by":"publisher","first-page":"11385","DOI":"10.1128\/JVI.01363-09","volume":"83","author":"CL Wohlford-Lenane","year":"2009","unstructured":"Wohlford-Lenane, C. L. et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol 83, 11385\u201311390, https:\/\/doi.org\/10.1128\/JVI.01363-09 (2009).","journal-title":"J Virol"},{"key":"53402_CR37","doi-asserted-by":"publisher","unstructured":"Bensman, T. J. et al. Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother 61, https:\/\/doi.org\/10.1128\/AAC.00154-17 (2017).","DOI":"10.1128\/AAC.00154-17"},{"key":"53402_CR38","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0428OC","author":"JG Jayne","year":"2017","unstructured":"Jayne, J. G. et al. Rhesus Theta (theta)-Defensin-1 Attenuates Endotoxin-Induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol. https:\/\/doi.org\/10.1165\/rcmb.2016-0428OC (2017).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"53402_CR39","doi-asserted-by":"publisher","unstructured":"Basso, V. et al. Fungicidal potency and mechanisms of theta-defensins against multi-drug resistant Candida species. Antimicrob Agents Chemother, https:\/\/doi.org\/10.1128\/AAC.00111-18 (2018).","DOI":"10.1128\/AAC.00111-18"},{"key":"53402_CR40","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1128\/AAC.01750-10","volume":"55","author":"NP Wiederhold","year":"2011","unstructured":"Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R. & Patterson, T. F. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother 55, 3254\u20133260, https:\/\/doi.org\/10.1128\/AAC.01750-10 (2011).","journal-title":"Antimicrob Agents Chemother"},{"key":"53402_CR41","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1128\/AAC.00095-07","volume":"51","author":"G Chamilos","year":"2007","unstructured":"Chamilos, G., Lewis, R. E., Albert, N. & Kontoyiannis, D. P. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother 51, 2257\u20132259, https:\/\/doi.org\/10.1128\/AAC.00095-07 (2007).","journal-title":"Antimicrob Agents Chemother"},{"key":"53402_CR42","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1128\/AAC.48.9.3407-3411.2004","volume":"48","author":"DA Stevens","year":"2004","unstructured":"Stevens, D. A., Espiritu, M. & Parmar, R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48, 3407\u20133411, https:\/\/doi.org\/10.1128\/AAC.48.9.3407-3411.2004 (2004).","journal-title":"Antimicrob Agents Chemother"},{"key":"53402_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1439-0507.2005.01121.x","volume":"48","author":"DM MacCallum","year":"2005","unstructured":"MacCallum, D. M. & Odds, F. C. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48, 151\u2013161, https:\/\/doi.org\/10.1111\/j.1439-0507.2005.01121.x (2005).","journal-title":"Mycoses"},{"issue":"(Pt 12)","key":"53402_CR44","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1099\/13500872-142-12-3487","volume":"142","author":"A Fulurija","year":"1996","unstructured":"Fulurija, A., Ashman, R. B. & Papadimitriou, J. M. Neutrophil depletion increases susceptibility to systemic and vaginal candidiasis in mice, and reveals differences between brain and kidney in mechanisms of host resistance. Microbiology 142((Pt 12)), 3487\u20133496, https:\/\/doi.org\/10.1099\/13500872-142-12-3487 (1996).","journal-title":"Microbiology"},{"key":"53402_CR45","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/iai.58.10.3319-3324.1990","volume":"58","author":"BJ Kullberg","year":"1990","unstructured":"Kullberg, B. J. van \u2018t Wout, J. W. & van Furth, R. Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 58, 3319\u20133324 (1990).","journal-title":"Infect Immun"},{"key":"53402_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1574-6968.2011.02262.x","volume":"320","author":"EK Szabo","year":"2011","unstructured":"Szabo, E. K. & MacCallum, D. M. The contribution of mouse models to our understanding of systemic candidiasis. FEMS Microbiol Lett 320, 1\u20138, https:\/\/doi.org\/10.1111\/j.1574-6968.2011.02262.x (2011).","journal-title":"FEMS Microbiol Lett"},{"key":"53402_CR47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/jac\/40.5.611","volume":"40","author":"DW Denning","year":"1997","unstructured":"Denning, D. W. Echinocandins and pneumocandins\u2013a new antifungal class with a novel mode of action. J Antimicrob Chemother 40, 611\u2013614 (1997).","journal-title":"J Antimicrob Chemother"},{"key":"53402_CR48","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1056\/NEJMe020142","volume":"347","author":"TJ Walsh","year":"2002","unstructured":"Walsh, T. J. Echinocandins\u2013an advance in the primary treatment of invasive candidiasis. N Engl J Med 347, 2070\u20132072, https:\/\/doi.org\/10.1056\/NEJMe020142 (2002).","journal-title":"N Engl J Med"},{"key":"53402_CR49","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/JCM.02390-09","volume":"48","author":"CD Pfeiffer","year":"2010","unstructured":"Pfeiffer, C. D. et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48, 2373\u20132380, https:\/\/doi.org\/10.1128\/JCM.02390-09 (2010).","journal-title":"J Clin Microbiol"},{"key":"53402_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1189\/jlb.0910535","volume":"89","author":"P Tongaonkar","year":"2011","unstructured":"Tongaonkar, P. et al. Rhesus macaque theta-defensin isoforms: expression, antimicrobial activities, and demonstration of a prominent role in neutrophil granule microbicidal activities. J Leukoc Biol 89, 283\u2013290, https:\/\/doi.org\/10.1189\/jlb.0910535 (2011).","journal-title":"J Leukoc Biol"},{"key":"53402_CR51","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri3897","volume":"15","author":"MG Netea","year":"2015","unstructured":"Netea, M. G., Joosten, L. A., van der Meer, J. W., Kullberg, B. J. & van de Veerdonk, F. L. Immune defence against Candida fungal infections. Nat Rev Immunol 15, 630\u2013642, https:\/\/doi.org\/10.1038\/nri3897 (2015).","journal-title":"Nat Rev Immunol"},{"key":"53402_CR52","doi-asserted-by":"publisher","first-page":"e1000639","DOI":"10.1371\/journal.ppat.1000639","volume":"5","author":"CF Urban","year":"2009","unstructured":"Urban, C. F. et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 5, e1000639, https:\/\/doi.org\/10.1371\/journal.ppat.1000639 (2009).","journal-title":"PLoS Pathog"},{"key":"53402_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jac\/dkv301","volume":"71","author":"PM Beringer","year":"2016","unstructured":"Beringer, P. M. et al. Rhesus theta-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa. J Antimicrob Chemother 71, 181\u2013188, https:\/\/doi.org\/10.1093\/jac\/dkv301 (2016).","journal-title":"J Antimicrob Chemother"},{"key":"53402_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrmicro732","volume":"1","author":"A Casadevall","year":"2003","unstructured":"Casadevall, A. & Pirofski, L. A. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1, 17\u201324, https:\/\/doi.org\/10.1038\/nrmicro732 (2003).","journal-title":"Nat Rev Microbiol"},{"key":"53402_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fchem.2019.00043","volume":"7","author":"EF Haney","year":"2019","unstructured":"Haney, E. F., Straus, S. K. & Hancock, R. E. W. Reassessing the Host Defense Peptide Landscape. Front Chem 7, 43, https:\/\/doi.org\/10.3389\/fchem.2019.00043 (2019).","journal-title":"Front Chem"},{"key":"53402_CR56","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1128\/AAC.00448-08","volume":"52","author":"PM Tavares","year":"2008","unstructured":"Tavares, P. M. et al. In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis. Antimicrob Agents Chemother 52, 4522\u20134525, https:\/\/doi.org\/10.1128\/AAC.00448-08 (2008).","journal-title":"Antimicrob Agents Chemother"},{"key":"53402_CR57","doi-asserted-by":"publisher","unstructured":"Freitas, C. G. et al. An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model. Antimicrob Agents Chemother 61, https:\/\/doi.org\/10.1128\/AAC.02518-16 (2017).","DOI":"10.1128\/AAC.02518-16"},{"key":"53402_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04462-6","volume":"7","author":"LP Menzel","year":"2017","unstructured":"Menzel, L. P. et al. Potent in vitro and in vivo antifungal activity of a small molecule host defense peptide mimic through a membrane-active mechanism. Sci Rep 7, 4353, https:\/\/doi.org\/10.1038\/s41598-017-04462-6 (2017).","journal-title":"Sci Rep"},{"issue":"1","key":"53402_CR59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/jof4010030","volume":"4","author":"Mobaswar Chowdhury","year":"2018","unstructured":"Chowdhury, M. H. et al. Antifungal Potential of Host Defense Peptide Mimetics in a Mouse Model of Disseminated Candidiasis. J Fungi (Basel) 4, https:\/\/doi.org\/10.3390\/jof4010030 (2018).","journal-title":"Journal of Fungi"},{"key":"53402_CR60","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1074\/jbc.RA117.000793","volume":"293","author":"JB Schaal","year":"2018","unstructured":"Schaal, J. B. et al. Macrocyclic theta-defensins suppress tumor necrosis factor-alpha (TNF-alpha) shedding by inhibition of TNF-alpha-converting enzyme. J Biol Chem 293, 2725\u20132734, https:\/\/doi.org\/10.1074\/jbc.RA117.000793 (2018).","journal-title":"J Biol Chem"},{"key":"53402_CR61","doi-asserted-by":"publisher","first-page":"e0187868","DOI":"10.1371\/journal.pone.0187868","volume":"12","author":"JB Schaal","year":"2017","unstructured":"Schaal, J. B. et al. Suppression and resolution of autoimmune arthritis by rhesus theta-defensin-1, an immunomodulatory macrocyclic peptide. PLoS One 12, e0187868, https:\/\/doi.org\/10.1371\/journal.pone.0187868 (2017).","journal-title":"PLoS One"},{"key":"53402_CR62","doi-asserted-by":"publisher","first-page":"e1002718","DOI":"10.1371\/journal.ppat.1002718","volume":"8","author":"SD Singh-Babak","year":"2012","unstructured":"Singh-Babak, S. D. et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog 8, e1002718, https:\/\/doi.org\/10.1371\/journal.ppat.1002718 (2012).","journal-title":"PLoS Pathog"},{"key":"53402_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0732-8893(02)00525-4","volume":"45","author":"E Canton","year":"2003","unstructured":"Canton, E. et al. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 45, 203\u2013206 (2003).","journal-title":"Diagn Microbiol Infect Dis"},{"key":"53402_CR64","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1128\/JCM.40.10.3776-3781.2002","volume":"40","author":"A Espinel-Ingroff","year":"2002","unstructured":"Espinel-Ingroff, A., Chaturvedi, V., Fothergill, A. & Rinaldi, M. G. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 40, 3776\u20133781 (2002).","journal-title":"J Clin Microbiol"},{"key":"53402_CR65","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1128\/CMR.17.2.268-280.2004","volume":"17","author":"MA Pfaller","year":"2004","unstructured":"Pfaller, M. A., Sheehan, D. J. & Rex, J. H. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 17, 268\u2013280 (2004).","journal-title":"Clin Microbiol Rev"},{"key":"53402_CR66","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1099\/jmm.0.007609-0","volume":"58","author":"CP Silveira","year":"2009","unstructured":"Silveira, C. P. et al. MICs and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazole and terbinafine in Sporothrix schenckii. J Med Microbiol 58, 1607\u20131610, https:\/\/doi.org\/10.1099\/jmm.0.007609-0 (2009).","journal-title":"J Med Microbiol"},{"key":"53402_CR67","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/nport.2008.141","volume":"3","author":"CG Pierce","year":"2008","unstructured":"Pierce, C. G. et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 3, 1494\u20131500, https:\/\/doi.org\/10.1038\/nport.2008.141 (2008).","journal-title":"Nat Protoc"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53402-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:56:14Z","timestamp":1671292574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53402-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53402"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53402-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Selsted (co-founder, chief scientific officer) and D.Q. Tran (scientific director) hold part time appointments with Oryn Therapeutics, LLC which has licensed theta defensin technologies for commercial development. Dr. Selsted receives no income from Oryn Therapeutics but is an equity holder. Dr. Tran is a part time employee of Oryn. The relationship between Oryn Therapeutics and USC is disclosed to and approved by all parties.\u00a0All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16905"}}